Celon Pharma (CLN) Q2 2025 earnings summary

Executive summary

• Group revenues for H1 2025 were PLN 105.9m, stable year-over-year, with generics growth offsetting a sharp decline in innovative segment grants.

• Generics segment showed strong growth in both domestic (+9% YoY) and export markets (+20% YoY), now comprising 95% of total revenues.

• EBITDA for generics rose to PLN 32.8m (+19.8% YoY), while innovative segment EBITDA loss deepened to PLN -43.8m.

• Net loss widened to PLN -58.1m from PLN -23.7m YoY, mainly due to lower grant income and sustained R&D investment.

• Cash position at June 30, 2025 was PLN 39m, down from PLN 75.1m at year-end, reflecting planned R&D outlays.

Financial highlights

• H1 2025 revenues: PLN 105.9m (0% YoY); Q2 2025 revenues: PLN 56.6m (-14% YoY).

• Drug sales for H1 2025 increased 13% YoY to PLN 99.6m.

• Operating costs rose 7% YoY to PLN 139.1m, impacting margins.

• H1 2025 EBIT: PLN -35.5m (+44% YoY loss); EBITDA: PLN -11.0m (vs. PLN 0.5m a year ago).

• Net loss: PLN -58.1m (vs. -PLN 23.7m YoY); EPS: -1.08 PLN (vs. -0.44 PLN YoY).

Outlook and guidance

• Revenue structure shift toward generics is expected to continue, with normalization of innovative segment funding anticipated as reimbursement delays resolve.

• Focus on expanding generics, especially Salmex, and advancing the innovative pipeline, with plans to introduce at least two new clinical candidates annually.

• Ongoing expansion in export markets and further development of the generics portfolio are strategic priorities.

• No formal financial guidance published for 2025.